Article Explains How Cannabis Could Be the “Holy Grail” of Neurological Medicine
San Diego, CA – July 25, 2016 – Medical Marijuana, Inc. (OTC: MJNA) announced today that its portfolio company Kannalife Sciences, Inc. (“Kannalife”) was the focus of a Forbes article that discussed the Kannalife’s role in developing a pharmaceutical treatment for the degenerative brain disorder Chronic Traumatic Encephalopathy (CTE), a concussion-related disease that is pervasive among NFL players.
The July 22 Forbes article titled, ”NFL To Name New Medical Chief, Bringing Hope for Cannabis Concussion Treatment,” describes how bio-pharmaceutical and phyto-medical company Kannalife is conducting U.S. government-licensed research to determine the effects of cannabinoids on CTE and how such research could lead to major changes in how the NFL treats and prevents players’ brain injuries. The article also includes success stories from former NFL players who have used medical marijuana instead of addictive opioid painkillers to address their brain injury-related symptoms.
In the article, Kannalife co-founder Thoma Kikis cites the plethora of athletes, including girls’ soccer players, which could benefit from Kannalife’s research. “We want to be able to have a pharmaceutical product that’s available the moment an injury happens,” Kikis told Forbes. “It would be great if the parents know what they’re giving their children. That it’s provided by a doctor and not from a dispensary.”
Scientific research studies have found that cannabidiol (CBD) reduces brain swelling and neurological impairment following a traumatic brain injury, which in turn improves recovery. Kannalife currently holds two licenses with the U.S. National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife to develop novel therapeutic drugs to treat CTE and hepatic encephalopathy (HE). While CBD from marijuana is tightly restricted, CBD found naturally in hemp is legal throughout all 50 states in the U.S.
“CTE can affect everybody from children who fall off their bikes, to combat veterans, to the professional NFL football players that were highlighted in this Forbes article,” said
Medical Marijuana, Inc. CEO Dr. Stuart Titus.
“Each time a story is written on the positive effects of cannabinoid therapeutics, hemp and marijuana – as well as cannabis derivatives such as CBD – we are one step closer to ‘access for all’ to this powerful botantical and its chemistry,” added Dr. Titus. “We are grateful for news organizations that continue spreading the word about the medical benefits of cannabis, which has the potential to effectively treat or prevent CTE, and for our Kannalife researchers who are on the front lines developing cannabinoid-based therapeutics and solutions.”
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit: www.Kannalife.com.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
- 888-829- 0070
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]